Alicia Morgans, MD, MPH, Discusses Outcomes From the CARD Trial in mCRPC at 2021 ESMO

Video
Conference|European Society for Medical Oncology Congress (ESMO)

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk survival and progression outcomes from the CARD trial in patients with metastatic castration-resistant prostate cancer.

At the 2021 European Society of Medical Oncology Congress, CancerNetwork® spoke with Alicia Morgans, MD, MPH, director of the Survivorship Program at Dana-Farber Cancer Center, about the progression and survival outcomes patient patients with metastatic castration-resistant prostate cancer at different time points throughout the phase 4 CARD trial (NCT02485691). Patients who enrolled on the trial were treated with either cabazitaxel (Jevtana) or a second androgen receptor inhibitor such as abiraterone (Zytiga) or enzalutamide (Xtandi) in order to compare costs and complications.

Transcript:

Interestingly, we found over time that the outcomes changed such that shorter term outcomes, [such as] progression decreased over the course of the study because at some point, patients did experience progression. The survival outcomes increased by the end of our follow-up period, as we really solidified mortality for some patients who had those unfortunate events. Ultimately, the reason we chose 18 months is that it was a nice time point to try to get a balanced picture. Between the 6-month shorter time points, and then our longer-term time points, it was just a nice place to report our primary findings.

Reference

Morgans AK, Hutson TE, Guan AK, et al. Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide). Presented at: 2021 European Society of Medical Oncology Congress; September 16-21, 2021; Virtual. Abstract 587P.

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Related Content
Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

April 15th 2024
Article

Sacituzumab tirumotecan elicited responses prominently in the second- and third-line and beyond setting and in those with high TROP2 expression.

Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.

Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy

January 1st 2024
Podcast

Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

AZD1390/Radiation Yields Encouraging Efficacy, Safety in Glioblastoma

April 9th 2024
Article

First-in-patient findings support AZD1390 as a potential radiosensitizer during the management of glioblastoma.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

The liquid biopsy combining miRNA and CA19-9 had the best validation rates for detecting pancreatic ductal adenocarcinoma.

miRNA Assay May Lead to Early Detection in PDAC

April 8th 2024
Article

The liquid biopsy combining miRNA and CA19-9 had the best validation rates for detecting pancreatic ductal adenocarcinoma.

Patients with advanced solid tumors may be able to stay on treatment with saruparib longer compared with other approved PARP inhibitors, thereby improving efficacy.

Saruparib Shows Favorable Activity, Safety in Mutant Advanced Solid Tumors

April 8th 2024
Article

Patients with advanced solid tumors may be able to stay on treatment with saruparib longer compared with other approved PARP inhibitors, thereby improving efficacy.